Patents by Inventor Jeremy Heidel

Jeremy Heidel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Reagents and Methods for Treating Cancer
    Publication number: 20160362693
    Abstract: This invention describes a genetic system for targeting the EVI1 gene in mammalian cells. The EVI1 gene is an oncogenic transcription factor that, when expressed, accelerates cell division and inhibits death of cells. Nucleotide sequences that block the expression of EVI1 and drug delivery systems for them are described. These nucleotide sequences cause a block in cell growth and division and trigger death of mammalian cells, including lung and ovarian cancer cells.
    Type: Application
    Filed: January 22, 2016
    Publication date: December 15, 2016
    Inventors: Thomas Primiano, Lonnie Bookbinder, Bey-Dih Chang, Jeremy Heidel
  • Compositions of a peptide targeting system for treating cancer
    Patent number: 9358308
    Abstract: This invention describes a protein nanoparticle system for targeting siRNA or other drugs into tumors. The basis of the protein system is elastin-like peptides that self-assemble once exposed to the nucleic acid of the siRNA. Specific targeting peptides are fused to the core ELP structure by standard genetic engineering techniques. These targeting peptides confer specific binding of the nanoparticle to receptors on the surface of tumor cells and allow for uptake of the nanoparticle into the tumor cells.
    Type: Grant
    Filed: February 7, 2014
    Date of Patent: June 7, 2016
    Assignee: NanoOncology, Inc.
    Inventors: Thomas Primiano, Bey-Dih Chang, Jeremy Heidel
  • Reagents and methods for treating cancer
    Patent number: 9273316
    Abstract: This invention describes a genetic system for targeting the EVI1 gene in mammalian cells. The EVI1 gene is an oncogenic transcription factor that, when expressed, accelerates cell division and inhibits death of cells. Nucleotide sequences that block the expression of EVI1 and drug delivery systems for them are described. These nucleotide sequences cause a block in cell growth and division and trigger death of mammalian cells, including lung and ovarian cancer cells.
    Type: Grant
    Filed: May 23, 2011
    Date of Patent: March 1, 2016
    Assignee: PeptiMed, Inc.
    Inventors: Thomas Primiano, Lonnie Bookbinder, Bey-Dih Chang, Jeremy Heidel
  • Compositions of a Peptide Targeting System for Treating Cancer
    Publication number: 20140220045
    Abstract: This invention describes a protein nanoparticle system for targeting siRNA or other drugs into tumors. The basis of the protein system is elastin-like peptides that self-assemble once exposed to the nucleic acid of the siRNA. Specific targeting peptides are fused to the core ELP structure by standard genetic engineering techniques. These targeting peptides confer specific binding of the nanoparticle to receptors on the surface of tumor cells and allow for uptake of the nanoparticle into the tumor cells.
    Type: Application
    Filed: February 7, 2014
    Publication date: August 7, 2014
    Applicant: NANOONCOLOGY, INC.
    Inventors: Thomas Primiano, Bey-Dih Chang, Jeremy Heidel
  • Compositions of a peptide targeting system for treating cancer
    Patent number: 8680045
    Abstract: This invention describes a protein nanoparticle system for targeting siRNA or other drugs into tumors. The basis of the protein system is elastin-like peptides that self-assemble once exposed to the nucleic acid of the siRNA. Specific targeting peptides are fused to the core ELP structure by standard genetic engineering techniques. These targeting peptides confer specific binding of the nanoparticle to receptors on the surface of tumor cells and allow for uptake of the nanoparticle into the tumor cells.
    Type: Grant
    Filed: November 1, 2011
    Date of Patent: March 25, 2014
    Assignee: PeptiMed, Inc.
    Inventors: Thomas Primiano, Bey-Dih Chang, Jeremy Heidel
  • Compositions of a peptide targeting system for treating cancer
    Publication number: 20120208742
    Abstract: This invention describes a protein nanoparticle system for targeting siRNA or other drugs into tumors. The basis of the protein system is elastin-like peptides that self-assemble once exposed to the nucleic acid of the siRNA. Specific targeting peptides are fused to the core ELP structure by standard genetic engineering techniques. These targeting peptides confer specific binding of the nanoparticle to receptors on the surface of tumor cells and allow for uptake of the nanoparticle into the tumor cells.
    Type: Application
    Filed: November 1, 2011
    Publication date: August 16, 2012
    Applicant: NANOONCOLOGY
    Inventors: Thomas Primiano, Bey-Dih Chang, Jeremy Heidel
  • Reagents and Methods for Treating Cancer
    Publication number: 20110293698
    Abstract: This invention describes a genetic system for targeting the EVI1 gene in mammalian cells. The EVI1 gene is an oncogenic transcription factor that, when expressed, accelerates cell division and inhibits death of cells. Nucleotide sequences that block the expression of EVI1 and drug delivery systems for them are described. These nucleotide sequences cause a block in cell growth and division and trigger death of mammalian cells, including lung and ovarian cancer cells.
    Type: Application
    Filed: May 23, 2011
    Publication date: December 1, 2011
    Applicant: NanoOncology, Inc.
    Inventors: Thomas Primiano, Lonnie Bookbinder, Bey-Dih Chang, Jeremy Heidel
  • Inhibitors of ribonucleotide reductase subunit 2 and uses thereof
    Publication number: 20060263435
    Abstract: The present application relates to inhibitors of ribonucleotide reductase subunit 2 (R2), and methods and compositions related to the R2 inhibitors. In certain embodiments, the R2 inhibitors include nucleic acids, such as for example siRNAs.
    Type: Application
    Filed: March 31, 2006
    Publication date: November 23, 2006
    Applicant: Calando Pharmaceuticals
    Inventors: Mark Davis, Jeremy Heidel, John Rossi